Long-Term Freedom From NMOSD Relapse With Satralizumab : vim

The use of the monoclonal antibody satralizumab for the long-term treatment of neuromyelitis optica spectrum disorder provides sustained freedom from relapse with no new safety concerns over 5 years.

Related Keywords

Denver , Colorado , United States , Tennessee , Canada , Vancouver , British Columbia , United Kingdom , British , Shailee Shah , Anthony Traboulsee , Consortium Of Multiple Sclerosis Centers , Neuroimmunology Division At Vanderbilt University Medical Center , University Of British Columbia , Drug Administration , Multiple Sclerosis Centers , Medscape Medical , Expanded Disability Status Scale , Good First Line , Medscape Medical News , Neuroimmunology Division , Vanderbilt University Medical Center , Multiple Sclerosis Ms , Multiple Sclerosis , Us , Biologic Therapy , Disability , Monoclonal Antibody , Etuximab , Ituximab , Neuromyelitis Optica Nmo , Devics Disease , Evics Syndrome , Eigg , Patient Safety , Adverse Effects , Side Effects , Boards , Smle , , Csf , Chronic Disease , Chronic Illness , Clinical Research , Clinical Trials , Linical Studies , Elderly Concerns Of Older Adults , Geriatrics Elder Care , Immunizat ,